The Withers tech team has advised biotech research firm Kynos Therapeutics on £9 million financing, consisting of £6.5 million led by Epidarex Capital together with IP Group and Scottish Enterprise. A further £2.5 million in Innovative UK grant funding was awarded for a Phase 1 clinical trial of lead KMO inhibitor.
A University of Edinburgh spin-out, Kynos’ initiatives are concentrated across three key areas: critical illness post-surgery, conditions driven by inflammation and in cancers where inflammation is preventing the immune system from fighting back.
Cambridge partner Susanna Stanfield, comments: “Kynos Therapeutics’ work is pioneering, and we are immensely proud to help the business raise such significant financing. The funds will enable them to continue supporting their lead KMO inhibitor programme through clinical trials, build out its core team and to fund further pre-clinical work.”
Withers tech is the technology, life sciences and venture capital focused team at international law firm Withers. The Withers tech team was led by Susanna, working alongside senior associates Sharmela Kalmer and Matt Peplow and associate Charlotte Berendt.
